XML 12 R2.htm IDEA: XBRL DOCUMENT v3.19.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2019
Dec. 31, 2018
Current assets:    
Cash and cash equivalents $ 169,222 $ 140,418
Restricted cash, current portion 2,000 0
Marketable securities 271,877 259,715
Interest receivable 766 375
Accounts receivable 12,095 4,673
Prepaid expenses and other current assets 5,848 5,340
Total current assets 461,808 410,521
Marketable securities, non-current 8,450 0
Property and equipment, net 21,019 78,723
Intangible assets 53,892 54,243
Goodwill 39,795 40,044
Operating lease right-of-use assets 79,435  
Other non-current assets 7,582 3,364
Non-current restricted cash 1,500 3,500
Total assets 673,481 590,395
Current liabilities:    
Accounts payable and accrued liabilities 22,505 21,457
Accrued compensation and employee benefits 8,714 9,490
Deferred revenues 50,826 47,564
Total current liabilities 82,045 78,511
Deferred revenues, non-current 94,189 108,273
Long-term portion of lease liabilities 41,550 27,689
Deferred income tax 6,661 6,705
Other non-current liabilities 3,288 1,960
Total liabilities 227,733 223,138
Commitments and contingencies
Stockholders' equity:    
Preferred stock 0 0
Common stock 1,156 1,022
Additional paid-in capital 1,078,976 929,632
Accumulated deficit (634,233) (562,696)
Accumulated other comprehensive loss (765) (1,440)
Total Sangamo Therapeutics, Inc. stockholders' equity 445,134 366,518
Non-controlling interest 614 739
Total stockholders' equity 445,748 367,257
Total liabilities and stockholders' equity $ 673,481 $ 590,395